Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Leibovich Score Is the Optimal Clinico-Pathological System Associated With Recurrence of Non-Metastatic ccRCC
  2. Limited Primary Tumour Responses in Patients Treated With Nivolumab for mRCC
  3. Neoadjuvant Nivolumab for High-Risk Nonmetastatic Renal Cell Carcinoma
  4. Novel Risk Scoring System for mRCC Patients Treated With Cabozantinib
  5. Impact of Primary Tumor Size on Prognosis in Patients With mRCC Receiving Cytoreductive Nephrectomy
  6. Mutant CDKN2A Regulates P16/p14 Expression by Alternative Splicing in RCC Metastasis
  7. ASCO 2021: Abstract Recommendations From Dr. Jun Gong for Genitourinary Cancer
  8. ASCO 2021: Abstract Recommendations From Dr. Jun Gong for Gastrointestinal Cancer
  9. Efficacy and Safety of Nivo/Ipi for Advanced or Metastatic Renal Cell Carcinoma
  10. Soluble BTN2A1 Is a Potential Biomarker in Pretreated Advanced RCC

Elsewhere

Recently Updated